NeuroOne Medical Technologies Corp. (NMTC) Enterprise Value to EBITDA Ratio
NeuroOne Medical Technologies (NMTC) maintains its position in a niche neurosurgery segment, developing systems for the therapy of Parkinson's disease and epilepsy. The EV/EBITDA valuation, which stands at 0.00 and assists in the basic asset assessment, is based on stable component supplies and the absence of logistical disruptions. Growth prospects rely on FDA approval of new products and the expansion of partner distribution networks for electrodes.
Comprehensive metric breakdowns and analytics for n1mtc.com (NMTC)
- current price and projected stock value:
- market capitalization details:
- business book valuation details:
- debt burden and liquidity indicators:
Total Debt to Equity Ratio NeuroOne Medical Technologies|NMTC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity NeuroOne Medical Technologies Corporation|NMTC - Company Total Debt|Debts to Book Capitalization NeuroOne Medical Technologies Corp.|NMTC - Long-Term Debt|Company Short-Term Debts NeuroOne Medical Technologies|Quick Ratio n1mtc.com
- financial results and valuation multiples details:
NMTC - Net Financial Result|Projected Future Earnings NeuroOne Medical Technologies|NMTC - Price to Earnings Ratio|Forward P/E Multiple NeuroOne Medical Technologies|NMTC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroOne Medical Technologies Corp.|NMTC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months NeuroOne Medical Technologies|NMTC - Earnings per share for the trailing year|Quarterly EPS earnings growth n1mtc.com|NMTC - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year NeuroOne Medical Technologies
Analysis of all company metrics:NeuroOne Corp NMTC
NeuroOne Medical Technologies investments in workforce expansion and the launch of new electrodes are creating a cash gap, increasing the company's reliance on external financing. The EV/EBITDA valuation trend compares the total enterprise value to its operating profit before interest, taxes, depreciation, and amortization, allowing investors to assess the real value of assets relative to the debt load and capital stability.
Competitor analysis
EV/EBITDA Multiple BSX (Boston Scientific Inc)|Total Company Value to Operating Income Before Depreciation Ratio Edwards Lifesciences Inc. (EW)|RMD: Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio PODD|ZBH: EV/EBITDA Multiple|Company Value to EBITDA The Cooper Companies, Inc. (COO)|ALGN (Align Technology Inc) - EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation GMED (NuVasive)|Enterprise Value to EBITDA Ratio TMDX (TransMedics)|ATEC (atecspine.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Artivion AORT|ENOV - Enterprise Value to EBITDA Ratio|Integra - EV/EBITDA Multiple|Company Value to EBITDA Establishment Labs Inc|BBNX: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation IRMD|EMBC (Embecta) - EV/EBITDA Multiple|Tandem Diabetes Care Inc (TNDM) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AXGN|Enterprise Value to EBITDA Ratio SI-BONE Medical SIBN|EV/EBITDA Multiple OFIX (Orthofix Medical Inc.)|EV/EBITDA Multiple bioventus.com BVS|KIDS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TMCI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SRTA (Strata Critical Medical Corp) - Enterprise Value to EBITDA Ratio|Carlsmed Medical - Business Value to Operating Income Before Depreciation|RXST (RxSight, Inc.) - EV/EBITDA Multiple|Company Value to EBITDA ClearPoint CLPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Stereotaxis (STXS)|Neuronetics Inc. (STIM) - Enterprise Value to EBITDA Multiple|Sight Sciences, Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple orchestrabiomed.com OBIO|Anika - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio inspiremd.com NSPR|zhjmedical.com (ZJYL) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio VANI (Vivani Medical)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xtant Medical Holdings, Inc.|Enterprise Value to EBITDA Ratio Modular Med (MODD)|EV/EBITDA Multiple MYO|COCH - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Vivos Therapeutics, Inc. VVOS|NVNO: Enterprise Value to Operating Income Before Depreciation|SINT: Enterprise Value to EBITDA Ratio|Tenon Medical Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ReWalk Robotics Ltd. (LFWD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AMIX|IVF (INVO Fertility) - EV/EBITDA Multiple|Company Value to EBITDA Bone Biologics Corp. BBLG|Enterprise Value to EBITDA Ratio AXNX (Axonics Modulation Technologies)|EV/EBITDA Multiple Biolase Inc. (BIOL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dynatronics DYNT|Business Value to Operating Income Before Depreciation FNA|INVO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
